|This Slide: #29 of 100|
Slide #29. Novartis — CoStim Pharmaceuticals, Inc.
CoStim Pharmaceuticals, Inc.
MPM Capital and Atlas Venture announced today that portfolio company CoStim Pharmaceuticals, Inc. ("CoStim") has been acquired by Novartis for an undisclosed amount. CoStim, founded in 2012 by MPM Managing Director Luke Evnin together with MPM Managing Director-Operations Robert Millman, is an emerging immuno-oncology company developing monoclonal antibody drugs that enable a patient's own immune system to better fight cancer.
Novartis is a holding company. Through its subsidiaries, Co. is a multinational group of companies focusing on the research, development, manufacturing and marketing of a range of pharmaceuticals and generic medicines. Co. comprises two divisions: Innovative Medicines, which researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two global business units, Novartis Oncology and Novartis Pharmaceuticals; and Sandoz, which develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients, and has three franchises, Retail Generics, Anti-Infectives and Biopharmaceuticals.
Open the NVS Page at The Online Investor »
Free NVS Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Buy (2.57 out of 4)